Search - tctmd.com

Displaying 1 - 20 of 26

Sort: Relevancy | Date

Meta-analysis: PFO Closure Beats Medical Therapy Alone in Preventing Recurrent Stroke

News Daily News

Meta-analysis: PFO Closure Beats Medical Therapy Alone in Preventing Recurrent Stroke

Yael L. Maxwell

December 22, 2017

Even After Recent ACS, Diabetic Patients With Multivessel Disease Fare Better With CABG

News Daily News

Even After Recent ACS, Diabetic Patients With Multivessel Disease Fare Better With CABG

December 11, 2017

Global Improvement in ACS Care Seen With Regional Clinical Pathway Implementation

News Conference News AHA 2017

Global Improvement in ACS Care Seen With Regional Clinical Pathway Implementation

Yael L. Maxwell

November 27, 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

News Conference News AHA 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Yael L. Maxwell

November 13, 2017

TRACER: Novel Device Effective in Reducing Severe Degenerative MR Over 6 Months

News Conference News TCT 2017

TRACER: Novel Device Effective in Reducing Severe Degenerative MR Over 6 Months

Yael L. Maxwell

November 01, 2017

Novel Percutaneous Suture-Based Solution for PFO Closure Shows Promise

News Conference News TCT 2017

Novel Percutaneous Suture-Based Solution for PFO Closure Shows Promise

Yael L. Maxwell

October 31, 2017

CULPRIT-SHOCK Disputes Benefit of Immediate Multivessel PCI in Patients With Cardiogenic Shock

News Conference News TCT 2017

CULPRIT-SHOCK Disputes Benefit of Immediate Multivessel PCI in Patients With Cardiogenic Shock

October 30, 2017

Women, Minorities at Greater Risk for Non-Stent-Related Events After PCI

News Daily News

Women, Minorities at Greater Risk for Non-Stent-Related Events After PCI

Yael L. Maxwell

October 20, 2017

Rivaroxaban Trial in Patients With Embolic Stroke of Undetermined Source Stopped Early

News Daily News

Rivaroxaban Trial in Patients With Embolic Stroke of Undetermined Source Stopped Early

October 09, 2017

As Percutaneous Mitral Valve Techniques Advance, Questions Turn to Combinations, Staging

News Conference News PCR London Valves 2017

As Percutaneous Mitral Valve Techniques Advance, Questions Turn to Combinations, Staging

September 26, 2017

New Performance and Quality Metrics for STEMI and NSTEMI Care

News Daily News

New Performance and Quality Metrics for STEMI and NSTEMI Care

Michael O'Riordan

September 21, 2017

Three New Positive PFO Closure Studies May Turn the Tide in Cryptogenic Stroke

News Daily News

Three New Positive PFO Closure Studies May Turn the Tide in Cryptogenic Stroke

Yael L. Maxwell

September 18, 2017

Rivaroxaban, Warfarin Provide Similar Results Early After Mild Strokes Related to A-fib

News Daily News

Rivaroxaban, Warfarin Provide Similar Results Early After Mild Strokes Related to A-fib

September 14, 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

August 27, 2017

Many Stroke Patients Stop Statins or Never Start, With Dire Consequences

News Daily News

Many Stroke Patients Stop Statins or Never Start, With Dire Consequences

Michael O'Riordan

August 02, 2017

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

News Daily News

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Michael O'Riordan

August 01, 2017

As Pragmatic Trials Gain Steam, Beware the Pitfalls of Claims Data

News Daily News

As Pragmatic Trials Gain Steam, Beware the Pitfalls of Claims Data

June 07, 2017

Two New Trials Buoy Outlook for PFO Closure in Patients With Cryptogenic Stroke

News Daily News

Two New Trials Buoy Outlook for PFO Closure in Patients With Cryptogenic Stroke

May 24, 2017

Rivaroxaban Appears to Protect Against MI in Older Men With A-fib, but Not in Women

News Daily News

Rivaroxaban Appears to Protect Against MI in Older Men With A-fib, but Not in Women

May 11, 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.